Coronavirus: Drugs

Department of Health and Social Care written question – answered on 11th October 2021.

Alert me about debates like this

Photo of Steven Baker Steven Baker Conservative, Wycombe

To ask the Secretary of State for Health and Social Care, whether his Department is (a) funding or (b) plans to fund the development of emerging covid-19 antibody therapy drugs (i) Ronapreve, (ii) Sotrovimab and (iii) AstraZeneca’s AZD7442.

Photo of Maggie Throup Maggie Throup The Parliamentary Under-Secretary for Health and Social Care

We are monitoring clinical trials and development of monoclonal antibodies including Ronapreve, Sotrovimab and AZD7442.

Ronapreve was part of the Government supported RECOVERY trial and in August the Medicines and althcare products Regulatory Agency approved Ronapreve as the first neutralising monoclonal antibody combination product for use in the prevention and treatment of COVID-19 in the United Kingdom. While we have not funded the development of Sotrovimab or AZD7442, company-funded trials for AZD7442 were prioritised by the National Institute for Health Research as urgent public health COVID-19 studies.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.